Stock 1801 INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
38.55 HKD +1.05% Intraday chart for Innovent Biologics, Inc. +14.39% -9.82%
Apr. 17 Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer CI
Apr. 02 Hutchmed endometrial cancer treatment application accepted for review AN

Evolution of the average Target Price on Innovent Biologics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

917144.pbKetjFurx76o8g_S4z5eZdwgUuMfZ5FI9f6RU-oQOo.zIT11UQt7Hul9q1aO7-9GKc-2SHYP_gEcY63CyvxCpPD5PqOXTbLJ53O_A~6d5bb76a60bbaf39fe0c2c5bf51afe7d

Analyst Recommendations on Innovent Biologics, Inc.

Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy MT
Nomura Adjusts Innovent Biologics’ Price Target to HK$54.51 From HK$45.73, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.73 From SG$54.72, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$54.72 From HK$45.44, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.44 From HK$45.38, Keeps at Buy MT
UBS Adjusts Innovent Biologics' Price Target to HK$42 From HK$39.30, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.38 From HK$43.75, Keeps at Buy MT
Hong Kong stocks down as tech shares slide ahead of Fed rate decision RE
Nomura Adjusts Innovent Biologics' Price Target to HK$43.75 From HK$49.41, Keeps at Buy MT
UBS Adjusts Innovent Biologics' Price Target to HK$43 From HK$60, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$49.41 From HK$58.18, Keeps at Buy MT
Nomura Adjusts Innovent Biologics Price Target to HK$58.18 From HK$92.73, Keeps at Buy MT
Tech stocks drag Hong Kong shares lower on U.S. rate hike concerns RE
INNOVENT BIOLOGICS : Nomura Adjusts Innovent's Price Target to HK$113.4 From HK$66.3, Keeps at Buy MT
Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
35.29 CNY
Average target price
51.42 CNY
Spread / Average Target
+45.69%
High Price Target
71.04 CNY
Spread / Highest target
+101.29%
Low Price Target
34.05 CNY
Spread / Lowest Target
-3.52%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Innovent Biologics, Inc.

Nomura
UBS

Ratings for Innovent Biologics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. Consensus Innovent Biologics, Inc.